Build status - In Progress
Search filters

Filters
Clear All

Phase

  • 67
  • 68
  • 1
  • 84
  • 1
  • 60
  • 13
  • 193
  • 563
  • 217
  • 9
  • 22
  • 535
  • 563
  • 3

Found 566 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 KEYMAKER-U02- substudy 02B
18 years - 99 years
All genders
Phase 1
Patients from Penn Medicine's Abramson Cancer Center will be approached for participation.This sub-study is part of a larger research study that is testing experimental treatments for melanoma. Various study drugs will be tested in combination with pembrolizumab in this study. Treatment groups include: a) MK-7684 and pembrolizumab b) pembrolizumab alone …
99 years or below
All genders
This is a prospective pilot study in which all eligible subjects will be randomized to treatment in the first phase and those with persistent or recurrent heart failure after Phase 1 therapy, may subsequently qualify to be randomized into Phase 2.
18 years - 99 years
Male
Interventional
This study involves research and is conducted to determine the safety, tolerability (how 6 your body reacts to the drug) and effectiveness of a study drug called REGN5678 which 7 will be given alone first and then be given in combination with cemiplimab.
99 years or below
All genders
Phase 1
This Phase 1b, open-label, multicenter study will be conducted to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in subjects with PAH currently ssing Tyvaso. A minimum of 45 patients from 15 sites in the US will be enrolled in the study.
99 years or below
All genders
Phase 2
Venous thromboembolism (VTE) is a major complication occurring in hospitalized subjects. Although anticoagulants and mechanical prophylaxis are commonly used to prevent VTE it remains a leading cause of complications and death in the hospital population. The objective of this study is to evaluate device design with respect to initial clinical …
99 years or below
All genders
Phase 2
The following protocol is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and SRS for recurrent GBM. We hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses. …
99 years or below
All genders
This is an interventional cohort study (n=10) that will involve external drainage of thoracic duct lymph in Surgical ICU patients with septic shock. The lymph drainage will continue for up to a maximum of 7 days and will be continued in those patients discharged from ICU back to the ward …
99 years or below
All genders
The success of behavioral weight loss is undermined by weight regain. Participants will be assessed at baseline and reassessed if they attain a minimum 7% weight loss (month 0) and undergo follow-up assessments 4 and 12-months later. Changes in physiological measures of metabolism and appetite during weight loss will be …
99 years or below
All genders
Phase 2
A multicenter, open label, randomized phase 2 study of I-131-1095 radiotherapy (less than or equal to 100 mCi/dose) every 8 weeks for up to 4 doses in combination with enzalutamide compared to enzalutamide alone in patients with progressive mCRPC. Patients must have documented progression on abiraterone and be indicated for …
99 years or below
All genders
Phase 2
Interventional
The purpose of this study is to determine the safety and efficacy of mitapivat in patients with sickle cell disease. Patients will be randomly assigned (like flipping a coin) in a 1:1:1 ratio to receive 50mg mitapivat, 100mg mitapivat or matched placebo for twice-daily oral administration. This means that you …
121 - 130 of 566